← Back to Stock Screener← Stock Screener

ZYBERNO

Stock Report

Updated Aug 31, 2026

CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV)

Healthcare • NASDAQ

$4.23

Professional Investment Analysis

ZYBERNO SCORE →

Is it a great business? Is it getting better?

35.0/100

WEAK BUSINESS

CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) scores 35/100 — weak fundamentals with mixed indicators requiring careful analysis before acting.

📊 How is the Zyberno Score calculated? +

The Zyberno Score answers one question: "Is this a quality business worth owning?" It's a 0-100 investment grade that evaluates business fundamentals across four critical dimensions, based on principles from Warren Buffett, Benjamin Graham, Peter Lynch, and Charlie Munger.

The 4 Core Categories (25 points each):

1. PROFITABILITY (25 pts)

Metrics: ROE, ROIC, Net Margin, Operating Margin
Thresholds: ROE >20% excellent • ROIC >20% excellent • Net Margin >20% excellent • Operating Margin >25% excellent

2. FINANCIAL STRENGTH (25 pts)

Metrics: Debt-to-Equity, Current Ratio, Interest Coverage, Altman Z-Score
Thresholds: D/E <0.3 excellent • Current Ratio >2.5 excellent • Interest Coverage >10x excellent • Altman Z >3.0 safe

3. CASH FLOW QUALITY (25 pts)

Metrics: Free Cash Flow, OCF vs Net Income, FCF Margin
Thresholds: Positive & growing FCF excellent • OCF/NI >1.2x excellent (cash earnings exceed accounting)

4. GROWTH & CONSISTENCY (25 pts)

Metrics: Revenue Growth, Net Income Growth, FCF Growth, Piotroski F-Score
Thresholds: Growth via log-linear regression • Piotroski 8-9 excellent, 6-7 good

Score Interpretation:

75-100

GREAT BUSINESS

65-74

GOOD BUSINESS

50-64

AVERAGE BUSINESS

30-49

WEAK BUSINESS

0-29

POOR BUSINESS

→ View full CLOV quality analysis & detailed breakdown

VALUATION SIGNAL

MARGIN OF SAFETY

Is this stock cheap or expensive relative to what the business has historically generated for owners?

-100.0%

Overvalued

Growth gap unavailable — insufficient data for reverse DCF calculation.

🎯 Expected Annual Return →

-48.4%

Margin of Safety convergence — your return if the market re-prices to intrinsic value (5-yr annualised)

4.1%

Yield + growth — what the business alone earns you, even if the market never re-rates

💰 How is Margin of Safety calculated? +

Margin of Safety measures how much discount or premium you're paying relative to a stock's intrinsic value. It's Benjamin Graham's core principle: the larger the margin, the lower your downside risk.

Formula: (Intrinsic Value − Current Price) ÷ Intrinsic Value × 100%

How We Calculate Intrinsic Value (DCF Method):

Step 1: Calculate current Owner Earnings (OCF − Maintenance CapEx)

Step 2: Calculate company-specific growth rate using log-linear regression on 16 quarters of Owner Earnings

Step 3: Project 10 years forward using the calculated growth rate

Step 4: Discount each year's cash flow to present value using 10% discount rate

Step 5: Calculate terminal value using 3% perpetual growth rate

Step 6: Sum all discounted cash flows = Intrinsic Value

What The Percentages Mean:

+50% or more

EXCELLENT — Very undervalued

+25% to +50%

GOOD — Attractive discount

0% to +25%

FAIR — Reasonable value

0% to -25%

CAUTION — Slight premium

-25% or worse

POOR — Overvalued

"Price is what you pay, value is what you get." — Warren Buffett

→ View full CLOV valuation analysis · → View full CLOV Brina Gap analysis

📈 How is Brina Gap calculated? +

Brina Gap measures the difference between the growth a business can fundamentally sustain and the growth the market is already pricing in.

Formula: Fundamental Growth Rate − Market-Implied Growth Rate

The Two Components:

Fundamental Growth Rate = ROIC × Reinvestment Rate

What the business can sustainably grow at based on how much it reinvests and what return it earns on that capital. Grounded in historical financials.

Market-Implied Growth Rate = Reverse DCF

The growth rate the current Enterprise Value implicitly assumes. Calculated by back-solving a 10-year DCF model (10% WACC, 3% terminal growth) until the present value of projected cash flows equals EV.

What The Gap Means:

Gap > +5% Market Underestimates — potential upside

+2% to +5% Slight Underestimate

-2% to +2% Fairly Priced — market consensus matches fundamentals

-5% to -2% Slight Overestimate

Gap < -5% Market Overestimates — price embeds optimism fundamentals don't support

A positive gap (market underestimates) combined with a positive Margin of Safety is the strongest combined signal — the business is both cheap historically and forward economics are stronger than the price suggests.

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-5.4%)

Debt-to-Equity (Solvency Risk):EXCELLENT (0.03x)

Operating Margin (Operational Efficiency):CRITICAL (-0.7%)

Return on Capital (Capital Efficiency):CRITICAL (-5.8%)

📊 Valuation Trilogy

Three interconnected metrics for complete valuation analysis

Click any metric for full methodology and detailed analysis

Zyberno's Verdict

CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) stock report — Zyberno Score 35/100 (WEAK BUSINESS), Margin of Safety -100.0%, -48% expected annual return. Full financial analysis on Zyberno.

According to Zyberno's DCF model, CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) trades at $4.23 against an estimated intrinsic value per share of $0.47 — a -100.0% Margin of Safety based on Owner Earnings of $55.41M TTM, projected at -32.6% growth for 10 years with a 2.5% terminal growth rate. Zyberno's model translates this into a 5-year expected return of -48.4% annually.

Over the trailing twelve months, CLOV generated $55.41M in Owner Earnings. Capital was deployed as follows: $2.71M invested in capital expenditures. Reinvestment rate: -28.2%. Owner Earnings have declined at 32.6% annually over the trailing five years using log-linear regression.

DIVISION I: EXECUTIVE SUMMARY

A. Market Valuation

Market Price & Capitalization (2)

Current Price:4.23

Market Cap:$2.22B

Valuation Multiples (3)

P/B Ratio:5.89x

P/S Ratio:0.90x

Peg Ratio:-999.00x

Enterprise Metrics (2)

Enterprise Value:$2.08B

Pfcf Ratio:40.65x

Price Action & Momentum (3)

12-1 Momentum:

+51.9% (90th pctile)

📈 Click to view full CLOV Momentum analysis →

Momentum Percentile:90 / 100

% of 52-Week High:75.7%

B. Profitability Assessment

Return Metrics (5)

ROE:

-5.4%

📊 Click to view full CLOV ROE analysis →

ROA:-2.9%

Roic:

-5.8%

📊 Click to view full CLOV ROIC analysis →

Reinvestment Rate:-28.2%

Fundamental Growth Rate (g):1.6%

Margin Analysis (3)

Operating Margin Ttm:-0.7%

Net Margin Ttm:-0.7%

Ebitda Margin:-0.8%

TTM Performance (3)

Gross Margin Ttm:13.5%

Operating Margin Ttm:-0.7%

Net Margin Ttm:-0.7%

Yield Metrics (3)

Earnings Yield:-$1.18

Owner Earnings Yield:$2.50

Dividend Yield:0.0%

C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

Earnings Surprise (SUE):

+0.01

📊 Click to view full CLOV Earnings Surprise analysis →

EPS Surprise vs Expected:3.9%

Latest Earnings Filed:2026-08-07

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-3.7%

Cash Flow Growth (Linear) (2)

Free Cash Flow Growth Rate (Linear):-32.9%

Operating Cash Flow Growth Rate (Linear):-31.9%

D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.50x

Quick Ratio:1.50x

Cash Ratio:0.60x

Leverage Analysis (3)

Debt To Equity Ttm:0.03x

Debt-to-Equity Ratio:0.03x

Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:162,116,000.00

Cash And Cash Equivalents:194,543,000.00

Long Term Debt:$20.74M

Net Debt:-$138.40M

DIVISION II: FINANCIAL STATEMENTS ANALYSIS

A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $2.48B

Linear Growth: -3.7%

📊 Click to view full CLOV Revenue analysis & methodology →

Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

Gross profit TTM: $333.15M

Linear Growth: 100.0%

📊 Click to view full CLOV Gross Profit analysis & methodology →

-$18.36M

Bottom Line Performance (3)

-$18.36M

Income Before Tax:-$85.55M

Ebitda Ttm:-19,135,000.00

Operating Expenses (5)

Operating Expenses:2,495,074,000.00

R And D Expense:0.00

Sga Expense:260,039,000.00

Income Tax Expense:$0.00

Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:0.0%

Sga To Revenue Percentage:35.0%

Ebitda Margin:-0.8%

B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$720.33M

Current Assets:$485.45M

Ppe Net:7,231,000.00

Goodwill:0.00

Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:344,069,000.00

Current Liabilities:323,330,000.00

Long Term Debt:$20.74M

Short Term Debt:$35.41M

Equity & Capital (3)

Equity:$376.26M

Retained Earnings:-$2.23B

Common Stock:0.00

Working Capital Items (3)

Accounts Receivable:0.00

Inventory:0.00

Accounts Payable:35,407,000.00

Special Items (2)

Contract Liabilities:17,000.00

Stock Based Compensation:8,904,000.00

C. Cash Flow Analysis

Operating Activities (2)

Operating cash flow TTM: $57.25M

Linear Growth: -31.9%

Free cash flow TTM: $54.54M

Linear Growth: -32.9%

📊 Click to view full CLOV Free Cash Flow analysis & methodology →

Investment Activities (2)

Investing Cash Flow:-$5.07M

Capital Expenditures Ttm:2,712,000.00

Financing Activities (3)

Financing Cash Flow:-$7.86M

Dividends Paid Ttm:0.00

Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:283,775,000.00

Long Term Debt Issuance:$0.00

Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:-774,000.00

DIVISION III: OPERATIONAL METRICS

A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.05

-$0.05

Earnings Per Share Ttm:-$0.04

Revenue & Cash Per Share (3)

Sales Per Share Ttm:4.72

Operating Cash Flow Per Share:-$0.13

Fcf Per Share Ttm:0.10

Book Value & Capital (2)

Book Value Per Share:$0.72

Cash Per Share:0.37

Dividend Policy (1)

Dividend Payout Ratio:-999.00x

B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:3.93x

Working Capital Turnover Ttm:15.28x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x

Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x

Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:5.22

Cash Conversion Cycle:-2,003.22

C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00

Quality Score:40.00

Market Metrics (2)

Beta:0.00x

Volatility Category:unknown

DIVISION IV: INVESTMENT ANALYSIS

A. Value Investment Framework

Owner Earnings Analysis (3)

Owner earnings TTM: $55.41M

Linear Growth: -32.6%

📊 Click to view full CLOV Owner Earnings analysis & methodology →

Owner Earnings Per Share:$0.11

Owner Earnings Yield:$2.50

Growth Assessment (1)

Owner Earnings Growth Rate:-$32.63

Damodaran Growth Analysis (2)

Reinvestment Rate:-28.2%

Fundamental Growth Rate (g):1.6%

Intrinsic Value Models (1)

Intrinsic Value:

$247.12M

📊 Click to view full CLOV DCF valuation →

Margin of Safety (1)

Margin Of Safety:

-100.0%

📊 Click to view full CLOV valuation analysis →

Return Scenarios (2)

Theoretical 5-Year Return:

-48.4%

📊 Click to view full CLOV expected return analysis →

Forward Expected Return (Yield + Growth):

4.1%

📊 Click to view full CLOV expected return analysis →

Investment Assessment (1)

Buffett Assessment:Overvalued

B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-3.7%

Cash Flow Growth Rates (2)

Free Cash Flow Growth Rate (Linear):-32.9%

Operating Cash Flow Growth Rate (Linear):-31.9%

Other Growth Rates (3)

Gross Profit Growth Rate (Linear):100.0%

Book Value Growth Rate (Linear):-2.0%

Owner Earnings Growth Rate:-$32.63

C. Company Profile & Context

Corporate Information (6)

Symbol:CLOV

Company Name:CLOVER HEALTH INVESTMENTS, CORP. /DE

Sector:Healthcare

Industry:Healthcare Services

Exchange:NASDAQ

Country:United States

Market Classification (3)

Market Cap Category:N/A

Price Category:low

Volume Category:N/A

Share Structure (3)

Shares Outstanding:524.19M

Shares Outstanding Basic:524.19M

Shares Outstanding Diluted:545.45M

Data Processing Info (3)

Processing Version:v3.0

Last Updated:2026-08-31 04:05:55 UTC

Data Timestamp:2026-08-31T04:05:55.206204